2.17
-0.09 (-3.98%)
| Penutupan Terdahulu | 2.26 |
| Buka | 2.29 |
| Jumlah Dagangan | 152,252 |
| Purata Dagangan (3B) | 44,022 |
| Modal Pasaran | 32,463,064 |
| Harga / Jualan (P/S) | 0.810 |
| Harga / Buku (P/B) | 1.31 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -7.98% |
| Margin Operasi (TTM) | 11.03% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 37.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 36.84% |
| Nisbah Semasa (MRQ) | 1.25 |
| Aliran Tunai Operasi (OCF TTM) | 5.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.56 M |
| Pulangan Atas Aset (ROA TTM) | -2.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Cumberland Pharmaceuticals Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | 0.13 |
|
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 41.55% |
| % Dimiliki oleh Institusi | 28.76% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JONES JAMES | - | - | 0 | 0 |
| KAZIMI A J | - | - | 0 | 0 |
| KROGULSKI KENNETH | - | - | 0 | 0 |
| YOUNG CAROLINE | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KROGULSKI KENNETH | Pengarah | 28 Nov 2025 | 124 | - | - | |
| KAZIMI A J | Pegawai | 28 Nov 2025 | 18 | - | - | |
| JONES JAMES | Pengarah | 28 Nov 2025 | 18 | - | - | |
| YOUNG CAROLINE | Pengarah | 28 Nov 2025 | 4 | - | - | |
| KROGULSKI KENNETH | Pengarah | 26 Nov 2025 | 124 | - | - | |
| KAZIMI A J | Pegawai | 26 Nov 2025 | 18 | - | - | |
| JONES JAMES | Pengarah | 26 Nov 2025 | 18 | - | - | |
| YOUNG CAROLINE | Pengarah | 26 Nov 2025 | 4 | - | - | |
| KROGULSKI KENNETH | Pengarah | 25 Nov 2025 | 124 | - | - | |
| KAZIMI A J | Pegawai | 25 Nov 2025 | 18 | - | - | |
| JONES JAMES | Pengarah | 25 Nov 2025 | 18 | - | - | |
| YOUNG CAROLINE | Pengarah | 25 Nov 2025 | 4 | - | - | |
| KROGULSKI KENNETH | Pengarah | 24 Nov 2025 | 124 | - | - | |
| KAZIMI A J | Pegawai | 24 Nov 2025 | 18 | - | - | |
| JONES JAMES | Pengarah | 24 Nov 2025 | 18 | - | - | |
| YOUNG CAROLINE | Pengarah | 24 Nov 2025 | 4 | - | - | |
| KROGULSKI KENNETH | Pengarah | 21 Nov 2025 | 117 | - | - | |
| KAZIMI A J | Pegawai | 21 Nov 2025 | 17 | - | - | |
| JONES JAMES | Pengarah | 21 Nov 2025 | 17 | - | - | |
| YOUNG CAROLINE | Pengarah | 21 Nov 2025 | 4 | - | - | |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Nov 2025 | Pengumuman | CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH |
| 28 Oct 2025 | Pengumuman | CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE |
| 20 Oct 2025 | Pengumuman | CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO |
| 20 Oct 2025 | Pengumuman | RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal |
| 13 Oct 2025 | Pengumuman | CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. |
| 01 Oct 2025 | Pengumuman | CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO |
| 29 Sep 2025 | Pengumuman | TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |